Venetoclax with stem cell transplant for first-remission acute myeloid leukemia
Treatments studied
Part of Blood & lymphatic, Cancer clinical trials.
This study tests whether adding venetoclax (a targeted pill that helps kill leukemia cells) to a stem cell transplant, and continuing it afterward, improves outcomes compared to a placebo. It is for people with acute myeloid leukemia (AML) in their first remission who are getting a reduced-intensity transplant.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are in first complete remission from acute myeloid leukemia (AML) after initial treatment.
- You have a stem cell donor that is either fully matched or half-matched (haploidentical) or somewhat mismatched.
- You are between ages 18 and 75 (depending on the donor type; some groups are 40–75).
- You have not had a prior stem cell transplant.
- You have adequate kidney, liver, lung, and heart function (for example, a heart ejection fraction of at least 40%).
- You can take oral medications and have no known severe allergies to the study drugs.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether adding venetoclax (a pill that targets cancer cells) to the standard chemotherapy regimen before a stem cell transplant improves outcomes for people with high-risk acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS). It is for patients aged 12–60 whose cancer has specific high-risk features and who have a matched donor.
This study tests whether adding venetoclax to a specific busulfan-based chemotherapy plan improves outcomes for people with high-risk AML or MDS. It mainly targets patients whose leukemia/marrow disease still has high-risk features or measurable disease after initial treatment.
This trial tests combining the medicine Venetoclax with a mini stem-cell transplant from a partially matched relative for people with newly diagnosed acute myeloid leukemia (AML). It may help control the leukemia while reducing transplant side effects.
This trial tests whether a reduced-intensity stem cell transplant or venetoclax-based pills work better for patients aged 60-75 with high-risk acute myeloid leukemia who are already in remission.
This trial tests whether giving Venetoclax and Azacitidine (VA) after your first remission helps keep you in remission before a stem cell transplant. It's for people with intermediate-risk AML who are planning to have a donor transplant.
This trial tests adding venetoclax to standard chemotherapy to help people with newly diagnosed acute myeloid leukemia (AML) or high-risk MDS (MDS-EB-2) live longer and reduce cancer activity. You may benefit if you’re eligible for intensive chemotherapy and meet specific blood, organ, and treatment timing requirements.
Hear when a new Acute Myeloid Leukemia trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.